Monday, November 27, 2017

Denali Therapeutics Sets IPO Pricing Range

San Francisco-based Denali Theaprutics, a biopharmaceuticals developer working on developing treatments for patients with neurodegenerative diseases like Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), has set its estimated IPO pricing. The company filed an updated S-1 on Monday saying it now expects to offer up 8,333,333 shares of its common stock at between $17.00 and $19.00 per share. The company has applied to list on the NASDAQ Global Select Market as DNLI. Denali's IPO is being underwritten by Goldman Sachs & Co., Morgan Stanley, J.P. Morgan, and Evercore ISI. The company is venture backed by AKDL, ARCH Ventures, flagship Ventures, F-Prime Capital Partners, and FIL Limited, among others. Denali's president and CEO is Ryan J. Watts, Ph.D.